The 203^rd meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Monday, January 30, 2023. Dr. Hugh Auchincloss, Acting Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair.

NIH published the Notice of Special Interest (NOSI)—Research on Early Allergy Determinants using Biosamples from the SUNBEAM Birth Cohort on July 27, 2023. Potential applicants should also refer to the CoFAR-12 SUNBEAM Protocol, Version 8 (PDF).

Several factors can increase a person’s risk for food allergies. These include

The University of Tennessee Regional Biocontainment Laboratory (RBL) is one of the NIAID-supported Biocontainment Laboratories. The RBL provides a secure lab for conducting research on Category A and B infectious pathogens using state-of-the-art molecular pathogenesis and immunologic approaches.

The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.

The University of Missouri Laboratory for Infectious Disease Research (LIDR) is one of the NIAID-supported Biocontainment Laboratories. LIDR facilitates research by University of Missouri faculty and collaborators to develop novel vaccines, diagnostics, and therapeutics against emerging infectious diseases and other biothreats.

The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories. The Lab provides a valuable national resource and asset to the University of Louisville, the region, and the greater scientific and public health communities. The Lab has been built to the most stringent federal standards.

The University of Chicago Howard Taylor Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories.  The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.

Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), located at The University of Alabama at Birmingham (UAB), is one of the 12 NIAID-funded Regional Biocontainment Laboratories (RBL). Construction of this 43,500 square foot research building was completed in 2008 and SEBLAB was fully operational in 2009. Laboratory space includes one BSL-2 suite, six BSL-3 suites for in vitro research, four ABSL-3 labs for small animal studies, and an in vivo imaging suite.